Minoryx Therapeutics, new drugs for minority diseases
Minoryx Therapeutics, winner of Senen Vilaró Prize, is a company specialized in the discovery and development of new drugs to treat rare diseases, which have a high socioeconomic cost for both the patients and families, and national health systems. In 2015, the University of Barcelona spin-off closed a round of funding valued at 19,4 million euros, the highest round reached by a biotec in Catalonia up to that moment, led by Ysios Capital and with the participation of Caixa Capital Risc, Health Equity and international investors such as Roche Venture Fund, Kurma Partners and Chiesi Ventures.
Minoryx Therapeutics, winner of Senen Vilaró Prize, is a company specialized in the discovery and development of new drugs to treat rare diseases, which have a high socioeconomic cost for both the patients and families, and national health systems. In 2015, the University of Barcelona spin-off closed a round of funding valued at 19,4 million euros, the highest round reached by a biotec in Catalonia up to that moment, led by Ysios Capital and with the participation of Caixa Capital Risc, Health Equity and international investors such as Roche Venture Fund, Kurma Partners and Chiesi Ventures.
With this funding, Minoryx expanded its team to promote the R&D area and started stage 1 clinical studies of the drug MIN-102 for the treatment of Adrenoleukodystrophy (X-ALD), a neurodegenerative disease with a severe prognostic which affects one out of 17.000 births. At this moment there is no drug treatment for this minority disease and the only alternative is the bone marrow transplant.